For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
All Authors
AS

HCP Connect Contributor

Dr. Arjun Sharma

Dr. Arjun Sharma contributes cardiology drug update coverage for HCP Connect, with emphasis on source-verified therapeutic developments and practical clinical context for US-licensed practitioners. This profile links the author's recent clinical coverage, specialty focus, and professional contributor metadata in one place.

Recent Drug Updates

15 total

Cardiology

FDA Approves Semaglutide for HFpEF: 20% Reduction in Heart Failure Events

Semaglutide approved for HFpEF: 20% reduction in heart failure events. Key implications for clinicians.

May 14, 2026|3 min read|Via FDA

Cardiology

Enlicitide Reduces LDL Cholesterol Significantly in Phase 3 Trial

Enlicitide reduces LDL cholesterol by 47% in HeFH patients, offering a new oral PCSK9 inhibitor option.

May 7, 2026|3 min read|Via NEJM

Cardiology

FDA Approves Semaglutide for PAD: 13% Improvement in Walking Distance in STRIDE Trial

Semaglutide approved for PAD: 13% walking distance improvement in STRIDE trial. Learn more about the implications for treatment.

May 7, 2026|2 min read|Via The Lancet

Cardiology

FDA Approves Semaglutide for HFpEF: 52% Improvement in Heart Failure Symptoms

Semaglutide improves heart failure symptoms by 52% in HFpEF patients, marking a significant advancement in treatment options.

May 6, 2026|3 min read|Via NEJM

Cardiology

FDA Approves Semaglutide for Peripheral Artery Disease: STRIDE Trial Shows Improved Walking Distance

FDA approves semaglutide for peripheral artery disease: 30% improvement in walking distance in STRIDE trial.

May 6, 2026|3 min read|Via FDA

Cardiology

FDA Approves Enlicitide for LDL Cholesterol Reduction: 30% Decrease in Phase 3 Trial

FDA approves Enlicitide for LDL cholesterol reduction: 30% decrease in Phase 3 trial results.

May 5, 2026|3 min read|Via FDA

Cardiology

FDA Approves Empagliflozin for HFpEF: 21% Reduction in CV Events

Empagliflozin approved for HFpEF: 21% CV event reduction in EMPEROR-Preserved trial.

May 2, 2026|3 min read|Via FDA

Health Information

Revive Dull Skin in 30 Days with Advanced Techniques

Discover how to restore your glow and boost confidence with proven skincare methods, tackling the top concern of 56% of Gen Y individuals.

Apr 23, 2026|6 min read|Via Health Soothe

Medical Research

Detect Pathogens 50% Faster with RNA Cas12a Assay

Improve disease diagnosis with a sensitive multi-guide RNA Cas12a assay, enabling early intervention and personalized treatment for tuberculosis and other poverty-linked diseases.

Apr 21, 2026|33 min read|Via Nature Communications

Health Information

Vaping vs Smoking: Impact on Dental Health

Learn how vaping and cigarette smoking affect oral hygiene, gum health, and tooth discoloration to better advise your patients on dental care.

Apr 19, 2026|3 min read|Via Health Soothe

Healthcare Business

Boost Arrhythmia Management with Data-Driven Insights

Discover how remote patient monitoring and AI can enhance symptom management, treatment effectiveness, and complication prevention in arrhythmia care.

Apr 18, 2026|2 min read|Via American Journal Managed Care

Medical Research

Reduce Seizures 30% with Precise DBS Targeting

Discover how precise deep brain stimulation targeting can reduce seizures by 30% in patients with drug-resistant epilepsy, offering new hope for improved outcomes.

Apr 7, 2026|4 min read|Via Medical Xpress

Medical Research

Gambling Harms Quadruple Youth Suicide Risk

New UK study reveals link between problem gambling and increased suicide risk in young people, with quadrupled risk four years later, informing clinicians on potential intervention...

Apr 6, 2026|2 min read|Via Medical Xpress

Medical Research

Delay Hep B Shot to Age 4: Impact on Pediatric Care

Discover the potential benefits of delaying the hepatitis B vaccine until age 4 and its implications for pediatric care and vaccine schedules.

Apr 6, 2026|9 min read|Via Medical Xpress

Health Information

Reduce Rheumatoid Arthritis Risk by 60%

Identify 11 key risk factors and take proactive steps to minimize your patients' likelihood of developing rheumatoid arthritis, a potentially disabling autoimmune disease.

Apr 2, 2026|8 min read|Via MedlinePlus
Dr. Arjun Sharma | HCP Connect Authors | HCP Connect